NUORTHO SURGICAL NAMED AS ONE OF TOP 50 COMPANIES TO WATCH IN 2010
FALL RIVER, MA (June 2010) – NuOrtho Surgical, Inc has been recognized by Medical Device and Diagnostic Industry (MD+DI) magazine as one of the top 50 companies to watch for in the medical device industry in 2010. NuOrtho Surgical is focused on surgical instruments that enable Tissue Preservation℠ in the Orthopedic arena to improve patient outcomes.
MD+DI went through a meticulous process to analyze all possible information on the nominated companies to select the final Top 50 companies. In the recent June 2010 publication, the magazine writes “The challenge for MD+DI editors was to identify not only those companies that have achieved success, but also to find those manufacturers with the potential to revolutionize care practices”.
CEO of NuOrtho Surgical, Jeffrey Morrill, commented “We are honored that MD+DI recognizes NuOrtho Surgical as one of the companies that can revolutionize care practices. As the population ages, there is a growing need to sustain long-term mobility, particularly among baby boomers. The future is bright for innovative products like ours that have a clear point of difference and benefits.
NuOrtho has completed 510K FDA regulatory filing and is awaiting clearance for Ceruleau™ an orthopedic probe which is designed to remove damaged cartilage and preserve healthy tissue during surgery. Mr Morrill added “MD+DI reported that they often selected companies that ‘often boasted ground breaking technologies.’. We believe Ceruleau™ and other products in our portfolio have enormous potential and it is rewarding for the Company to be recognized in this way”.
MD+DI solicited nominations from readers, its Editorial Advisory Board and Reader Board, and industry observers, and analyzed nominee information before producing the list.
NuOrtho Surgical is focused on the manufacture of surgical instruments that enable Tissue Preservation™ in the orthopedic arena to improve patient outcomes. NuOrtho has three primary product platforms for preserving healthy tissue to sustain long-term mobility. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. NuOrtho’s first product launch will be Ceruleau™, a revolutionary product for soft tissue treatment in knee procedures for cartilage. The company has a growing patent portfolio, as they added another one recently, providing significant business opportunities.